BioCentury | Jan 15, 2021
Product Development
Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C
Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology. The New York-based company will use the funds to speed development of clinical applications,...